Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 106,038

Document Document Title
WO/2015/016206A1
The present invention provides a prophylactic or therapeutic agent for autoimmune disease (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythe...  
WO/2015/013865A1
Disclosed are agomelatine sulfonic acids complexes having the specific stoichiometry of 2 molar equivalents of agomelatine for 1 molar equivalent of sulfonic acids. Those complexes show excellent solubility, stability and purity, making ...  
WO/2015/014838A1
The present invention relates to an inhibitor of neurocalcin delta (NCALD) for use in a method for the treatment or prevention of a patient suffering from a disorder associated with a pathological calcium homeostasis. Furthermore, the pr...  
WO/2015/016695A1
The present invention relates to stable pharmaceutical compositions comprising a tablet/tablet system, consisting of the compression of a tablet within another tablet with a biphasic-delivery system of at least one analogue of (1R, 2R)-2...  
WO/2015/017280A1
The present invention relates to compositions and methods for the prevention and treatment of neurodegenerative diseases, such Alzheimer's disease, that are caused by misfolding, aggregating proteins. The compositions and methods of the ...  
WO/2015/014816A1
The invention refers to compounds of general formula (I) wherein the variables take various meanings, pharmaceutical compositions containing them and their use in medicine, particularly in pain therapy.  
WO/2015/017412A1
The disclosure includes compounds and pharmaceutically acceptable salts of Formula (I). Certain compounds and salts of Formula (I) are selective inhibitors of the Dopamine D2 receptor. The variables R1-R4, n, and L are defined herein. Th...  
WO/2015/014256A1
Provided herein are novel heteroaryl compounds, pharmaceutically acceptable salts and pharmaceutical formulations thereof for selectively inhibiting serotonin reuptake and/or acting as 5-HT1A receptor agonists. Also provided herein are p...  
WO/2015/016285A1
Provided is a brain function-improving composition which can inhibit binding of homocysteic acid to a receptor (NMDA receptor) and, at the same time, decrease the binding ability of homocysteic acid per se to the receptor to thereby impr...  
WO/2015/015185A1
A method for producing an engineered tissue scaffold for neural repair is described. The method includes tethering a hydrogel matrix seeded with tension-generating cells to a frame, and allowing the tension-generating cells to generate t...  
WO/2015/014442A1
Compounds of the formula I in which R1-R3 and Z have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous ...  
WO/2015/017715A1
The present invention relates to a new drug delivery strategy based on prodrug conversion, in which a water-soluble prodrug and its converting enzyme are co-delivered and at a point of administration such as the nasal or buccal mucosa. E...  
WO/2015/017407A1
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I, wherein variables A4, A5, A6, A8, R1, R2, R3, R7and n of Formula I, indep...  
WO/2015/013903A1
The present invention relates to the p-toluenesulfonic acid co-crystals of agomelatine of formula (I), preparation and use thereof, and to pharmaceutical composition containing it. The p-toluenesulfonic acid co-crystals of agomelatine ob...  
WO/2015/014884A1
The invention relates to a fusion protein comprising an antibody directed to Aβ, a monovalent binding entity which binds to a blood brain barrier receptor and a neprilysin.  
WO/2015/016667A1
The present invention relates to an orally disintegrating film preparation containing donepezil, and a preparation method therefor and particularly, to an orally disintegrating film preparation for treating dementia, containing donepezil...  
WO/2015/017123A1
The present disclosure relates, in one aspect, to use of ghrelin splice variant or an analogue thereof, or a ghrelin splice variant-like compound for the preparation of a medicament for one or more of: treatment and/or prevention of neur...  
WO/2015/010210A1
Compounds of general formula (I) and their use to reduce circulating acylated ghrelin levels are provided. GSA-X-Y-B (I) in which "GSA-X" is a ghrelin moiety, "Y" is an optional peptide linker and "B" is a CPP moiety. The compounds of ge...  
WO/2015/011038A1
Compositions contain a therapeutically effective amount of tiglic aldehyde for at least one of provoking the swallowing reflex of dysphagic patients, decreasing appetite by delaying gastric emptying, reducing body weight gain, or reducin...  
WO/2015/010655A1
Triadic fused cyclic carboxylic acids derivatives, preparation method therefor and pharmaceutical use thereof, particularly relating to compounds represented by general formula (I), stereoisomers, hydrates, solvates, metabolites, eutecti...  
WO/2015/011037A1
Compositions contain a therapeutically effective amount of cuminaldehyde for at least one of provoking the swallowing reflex of dysphagic patients, decreasing appetite by delaying gastric emptying, reducing body weight gain, or reducing ...  
WO/2015/012708A1
A compound having a structure selected from the following: or a pharmaceutically acceptable salt thereof. The compound may be used as an inhibitor of fatty acid amide hydrolase.  
WO/2015/011036A1
Compositions contain a therapeutically effective amount of p-anisaldehyde for at least one of provoking the swallowing reflex of dysphagic patients, decreasing appetite by delaying gastric emptying, reducing body weight gain, or reducing...  
WO/2015/012704A1
This invention concerns pyrroloquinoline derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of su...  
WO/2015/011189A1
The present invention is concerned with an oral pharmaceutical dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain in ...  
WO/2015/012328A1
A compound represented by formula (I) [In the formula, each symbol is as described in the specification.] or a salt thereof has a PDE2A inhibitory action and is effective as a preventive and therapeutic agent for schizophrenia, Alzheimer...  
WO/2015/012400A1
The present invention provides a novel compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof, which, on the basis of glycine reuptake inhibiting action, is useful in prevention or treatment of d...  
WO/2015/011451A1
Compositions for use in a method of treatment, particularly for use in a method of treatment of epilepsy or an epilepsy-related disorder, are provided. Uses of the compositions are also described, along with methods for employing the com...  
WO/2015/010217A1
Dimiracetam or a solvate thereof is a suitable effective substance for being used in the treatment and/or prevention of depression.  
WO/2015/012780A1
The invention relates to medicine and the chemical and pharmaceutical industry, and more particularly to the creation, production and use of cerebroprotective agents for improving cerebral blood flood. The medicinal agent contains (in gr...  
WO/2015/013451A3
Provided are methods for enhancing hippocampal plasticity and hippocampal-mediated learning and memory, and/or enhancing the synaptic maturation of neurons, and/or optimizing or enhancing neuronal synaptic transmission, and/or enhancing ...  
WO/2015/011246A1
The present invention relates to the use of flecainide as an anti-connexin agent. This anti-connexin agent is advantageously used to potentiate the therapeutic effectof various psychotropic drugs. More specifically, the invention provide...  
WO/2015/011447A1
Provided are methods and materials for treating a neurological, behavioural, psychological, psychiatric, or personality disorder or syndrome in an individual, which disorder or syndrome is associated with a plurality of aberrant thoughts...  
WO/2015/012298A1
A compound represented by general formula (I) (I) has a strong Axl inhibiting activity by introducing a distinctive bicyclic structure in which a saturated carbocyclic ring is fused to a pyridone ring, and thus may be used as a therapeut...  
WO/2015/013318A1
This invention provides novel compounds of the following formula and pharmaceutical compositions containing such compounds.  
WO/2015/009195A1
The invention relates to novel substances, and more particularly to optical isomers of (+) and (-)-benzhydryl ureas of formula (I) and (+) and (-)-1-[(3-chlorophenyl)-phenyl-methyl] urea, a pharmaceutical composition based thereon, and a...  
WO/2015/010054A3
Described herein are neuroactive steroids of the Formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof; wherein R1a and R1b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GAB...  
WO/2015/008073A1
The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychi...  
WO/2015/009710A1
The present invention generally relates to compositions, reagents and methods for detecting and treating a neural tube defect in a fetus. One aspect of the invention provides a method including administrating a composition containing nog...  
WO/2015/008848A1
A self-emulsifying composition which comprises, when taking the total amount of the self-emulsifying composition as 100mass%, 70 to 90mass% of at least one compound selected from the group consisting of ω-3 polyunsaturated fatty acids, ...  
WO/2015/007249A1
An N-alkyl tryptanthrin derivative, a preparation method for same, and an application thereof. The structure of the derivative is as represented by formula I. The N-alkyl tryptanthrin derivative can serve as a highly active IDO inhibitor...  
WO/2015/009500A1
Anatabine is delivered in a volatilized form for treating substance addictions such as nicotine addiction, alcohol addiction, marijuana addiction, heroin addiction, or cocaine addiction. Devices such as electronic inhalers may be used fo...  
WO/2015/009008A1
The present invention relates to a novel adenine derivative and a pharmaceutical use thereof and, more specifically, to a novel adenine derivative having a structure of chemical formula 1 or a pharmaceutically acceptable salt thereof and...  
WO/2015/007191A1
The present invention belongs to pharmaceutical chemistry field. Paliperidone amino acids derivates and use thereof are disclosed After experiment, it is found that the compounds can be used for preparing medicant for treating mental dis...  
WO/2015/006829A1
The invention relates to a composition or method for treating at least one of infection, sepsis and injury or inducing a hypotensive state or a low pain or analgesic state in a subject susceptible to or suffering from at least one of inf...  
WO/2015/008206A1
The present invention provides compounds acting as Insulin/IGF signaling modulators useful in the treatment of neurodegenerative diseases and disorders. The invention provides pharmaceutical compositions including such compounds, and met...  
WO/2015/008849A1
A self-emulsifying composition which comprises, when taking the total amount of the composition as 100mass%, 70 to 90mass% of at least one compound selected from the group consisting of ω-3 polyunsaturated fatty acids, pharmaceutically ...  
WO/2015/007222A1
Provided is the discovery of the role of EphA4 signaling in neurodegenerative disorders involving β-amyloid induced neurotoxicity such as Alzheimer's Disease. New therapeutic methods, therapeutic agents, and kits for treating diseases c...  
WO/2015/009909A1
Generally provided herein are methods, compounds, and compositions described useful for the treatment of light chain amyloidosis and other amyloid protein diseases.  
WO/2015/007730A1
The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds ...  

Matches 451 - 500 out of 106,038